Theravance Biopharma (TBPH) Receivables (2013 - 2019)

Theravance Biopharma (TBPH) has reported Receivables for 7 consecutive years, with $20.1 million the latest figure, recorded in Q3 2019.

• In Q3 2019, Receivables rose 189.81% year-over-year to $20.1 million; the TTM figure through Sep 2019 stood at $20.1 million (up 189.81% YoY), while the FY2018 annual figure was $10.7 million, up 14.0% from the prior year.
• Receivables steadied at $20.1 million in Q3 2019 per TBPH's latest filing, from $20.1 million in the prior quarter.
• Across five years, Receivables topped out at $39.1 million in Q1 2016 and bottomed at $1.9 million in Q4 2015.
• Historically, Receivables has averaged $15.5 million across 5 years, with a median of $10.7 million in 2018.
• Annual changes were most pronounced in 2015 — Receivables surged 28479.35% — and 2017, when it tumbled 81.96%.
• Theravance Biopharma's Receivables stood at $1.9 million in 2015, then surged by 405.83% to $9.7 million in 2016, then dropped by 3.7% to $9.4 million in 2017, then grew by 14.0% to $10.7 million in 2018, then surged by 88.2% to $20.1 million in 2019.
• Business Quant data shows TBPH's Receivables at $20.1 million in Q3 2019, $20.1 million in Q2 2019, and $7.9 million in Q1 2019.